Lung transfection to cure lung cancer:

The treatments for cancer that are available today, such as chemotherapy, immunotherapy, and radiation, have shown great success; however, these medicines also come with a number of side effects that patients would rather not experience. One effective method for reducing these treatments’ cytotoxicity is to use a nanoparticle-mediated siRNA delivery approach. This method has selective silencing effects and utilizes non-viral vectors. In addition, the mitochondrial fusion pathway was used in conjunction with siOPA1 to induce apoptosis in the cells. The degree of stability of the OPA1 protein is essential for preserving the normal structure and function of mitochondrial cristae, preventing apoptosis in cells, and retaining the structure of the inner membrane. Consequently, the cell viability and cellular uptake were enhanced when FPS or siOPA1 was used to treat lung cancer in both in-vitro and in-vivo studies. 

Recombinant protein expression through lungs transfection: 

Researchers can get a deeper understanding of the practical role that a particular protein plays in regulating essential biological processes if protein expression is increased. This has often been accomplished in the lung by the use of genetic techniques such as transgenic mice, viral or non-viral vectors, or viral vectors, all of which enhance protein levels through increased gene expression. The production of transgenic mice is laborious, time-consuming, and expensive. Additionally, the arbitrary introduction of a transgenic or persistent gene expression may affect healthy lung development, which decreases the model’s value. This is because of the possibility for normal lung development to be disrupted. It is known that mice carrying the reverse tetracycline-controlled transactivator (rtTA) exhibit spontaneous air space expansion. These animals are used in the process of inducing conditional expression. 

On the other hand, conditional transgenics have the ability to avoid the problems that are connected to the persistent expression of genes. The use of viral and non-viral vectors, which is expensive and has the potential to generate dose-dependent inflammatory responses, is analogous to the practice of transgenics. These reactions might confuse findings and impede expression. In addition, the effectiveness of repeated treatments is restricted since increased immunological responses to the vector reduce its effectiveness. Researchers are working on Adeno-associated viral, or AAV, vectors that will have less of an inflammatory response and a longer expression time inside the lung.